In our previous analyses (2023[1] and 2024[2]), we tracked two oncology development cohorts using a Kaplan–Meier framework to visualize how quickly programs reach a terminal outcome—either an FDA approval or a discontinuation. We highlighted the growing use of expansion cohorts in FIH studies, and identified that commercial sponsors tend to move programs through development more […] The post Oncology Development Update: Winners, Losers, and the Ones Still in Play appeared first on Recon...
